Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 6/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.64 |
| ▸ | DRD1 | P21728 | 4/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.64 |
| ▸ | HTR2A | P28223 | 3/20 | 0.64 |
| ▸ | HRH1 | P35367 | 3/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.64 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.64 |
| ▸ | HTR2C | P28335 | 2/20 | 0.64 |
| ▸ | HTR2B | P41595 | 2/20 | 0.64 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | HTR6 | P50406 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorothen SCHEMBL29521748 | 0.99 | KDM4E (0.65) | CYP2D6CHRM2ADRA2ADRD1SLC6A4 | |
| Chlorothen SCHEMBL1649730 | 0.85 | LMNA (0.71) | CYP2D6CHRM2ADRA2ADRD1SLC6A4 | |
| SCHEMBL21360460 | 0.85 | CYP2D6 (0.46) | CYP2D6CHRM2ADRA2ADRD1SLC6A4 | |
| SCHEMBL10749933 | 0.83 | CYP2D6 (0.44) | CYP2D6CHRM2ADRA2ADRD1SLC6A4 | |
| SCHEMBL18912921 | 0.82 | CYP2D6 (0.43) | CYP2D6CHRM2ADRA2ADRD1SLC6A4 | |
| Methapyrilene SCHEMBL19209 | 0.78 | CYP2D6 (1.00) | CYP2D6CHRM2ADRA2ADRD1SLC6A4 | |
| Methapyrilene SCHEMBL745149 | 0.77 | CYP2D6 (0.97) | CYP2D6CHRM2ADRA2ADRD1SLC6A4 | |
| Methapyrilene SCHEMBL498484 | 0.77 | KDM4E (1.00) | CYP2D6CHRM2ADRA2ADRD1SLC6A4 | |
| Chloropyramine SCHEMBL30021 | 0.77 | CYP2D6 (1.00) | CYP2D6CHRM2ADRA2ADRD1SLC6A4 | |
| Chloropyramine SCHEMBL30566745 | 0.77 | CYP2D6 (1.00) | CYP2D6CHRM2ADRA2ADRD1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 556 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9492541-B2 | Phenylepherine containing dosage form | SOVEREIGN PHARMACEUTICALS, LLC (US) | 2016-11-15 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2014186623-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF A CHAGAS DISEASE | BIOMED VALLEY DISCOVERIES (US) | 2014-11-20 | — | — | WO | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-20080292699-A1 | SOLID PHARMACEUTICAL DOSAGE UNIT FOR ALLEVIATING SYMPTOMS OF RHINORRHEA | SOVEREIGN PHARMACEUTICALS, LTD. (US) | 2008-11-27 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| EP-1829527-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | claimed |
| EP-1829528-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | claimed |
| EP-1815846-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | claimed |
| EP-1815847-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | claimed |
| US-20050266032-A1 | Dosage form containing multiple drugs | SOVEREIGN PHARMACEUTICALS, LTD. (US) | 2005-12-01 | — | — | US | claimed |
| CN-1703199-A | Aggregate with enhanced deformability comprising at least three amphiphiles for improved transport through a semi-permeable barrier and use of non-invasive drugs in vivo, in particular through the skin | IDEA AG (DE) | 2005-11-30 | — | — | CN | claimed |
| EP-1551370-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2005-07-13 | — | — | EP | claimed |
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2004-06-03 | — | — | US | claimed |
| WO-2004032900-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2004-04-22 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-1998058685-A1 | DERMAL ADHESIVE PLASTER SUITABLE FOR TREATING LOCALIZED CUTANEOUS AFFECTIONS | LABORATORIO ITALIANO BIOCHIMICO FARMACEUTICO LISAPHARMA S.P.A. (IT) | 1998-12-30 | — | — | WO | claimed |
| EP-0039879-B1 | A SOFT CAPSULE AND PROCESS FOR THE PREPARATION OF THE SAME | Eisai Co., Ltd. (JP) | 1983-08-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | CUTA, ABCG2, PIGS | CYP2D6 632/4885CHRM2 2986/4885ADRA2A 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.